ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2166

Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis: A Clinical Educational Workshop

Ahmed Rubia1, Nancy Olsen2, Saurav Suman3, Sharon Banks4, Shirley Albano Aluquin1, Kristie Pepper5 and Rayford June6, 1Penn State Milton S. Hershey Medical Cen, Hershey, PA, 2Penn State University/Milton S Hershey, Hershey, PA, 3Penn State Milton S. Hershey Medical Cen, Harrisburg, PA, 4Penn State Milton S. Hershey Medical Center, Hershey, PA, 5Penn State Milton S. Hershey Medical Cen, Lebanon, PA, 6Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA

Meeting: ACR Convergence 2025

Keywords: Clinical practice guidelines, education, medical, Measurement, rheumatoid arthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2159–2194) Professional Education Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The Clinical Disease Activity Index (CDAI) is one of six assessment measures for rheumatoid arthritis (RA) recommended for management of RA in clinical practice. RA assessment measures were developed and validated for clinical research but since adoption of treat-to-target (TTT) principles as the standard of care for RA, there is a need for professional education to implement these measures in the clinic. As the CDAI does not require laboratory data, this RA composite outcome measure is preferred for the point-of-care management of RA. Standardization of joint examination technique has been shown to decrease interobserver variability in performing the CDAI. The purpose of this study was to create a medical educational workshop curriculum for learners and providers to improve knowledge and familiarity with the CDAI in RA management.

Methods: An educational workshop for the CDAI was developed and this curriculum proposal was presented at our institutional Rheumatology grand rounds for process improvement. Based on the feedback from this presentation, a 6-minute video demonstrating a 28 joint count exam was then developed (Image 1). 8 months later, Rheumatology providers and learners, including rheumatology fellows, were invited to a CDAI education workshop. The workshop included learning objectives, an 8-question pre-and 5 question post-workshop questionnaire, didactic presentation, a joint examination video followed by a series of three RA case discussions. Time was built in for group discussion on CDAI score on the RA cases. The workshop ended with a post-workshop questionnaire. Data were analyzed using descriptive statistics and t-tests to compare groups. A P value of < 0.05 was considered significant.

Results: The workshop was facilitated by a second-year rheumatology fellow and a rheumatology attending physician. There were 10 participants including rheumatology fellows, advanced practice providers, and attending physicians. All participants completed the pre and post-knowledge questionnaire (Table 1). The mean participant response for confidence in performing CDAI prior to the curriculum was a mean of 3 (SD 1.63), based on a 5-point Likert scale. After the curriculum, the likelihood of performing CDAI in clinic was a mean of 4.7 (SD 0.48). Prior to the workshop, confidence in performing the provider global was 3.1 (SD 1.54) and improved to 4.9 (SD 0.32). Similarly, confidence in assessing patient global activity, increased from 3.6 (SD 1.42) to 4.9 (SD 0.31) after the workshop. Overall, the participants responded that the course was helpful in increasing awareness and confidence in performing the CDAI. Pre and post means improved significantly after the workshop (p=0.0001) suggesting generalized knowledge improvement from the training workshop.

Conclusion: A clinical educational workshop on CDAI for Rheumatology providers improved self-reported knowledge of the CDAI for rheumatology training. Further investigation is needed to know if the education workshop translates into higher and proper utilization of CDAI in clinical care.

Supporting image 1Figure 1

Supporting image 2Table 1

Supporting image 3Image 1


Disclosures: A. Rubia: None; N. Olsen: Atare Bio, 5, GlaxoSmithKlein(GSK), 1, UCB, 5, Zenas, 5; S. Suman: None; S. Banks: None; S. Albano Aluquin: None; K. Pepper: None; R. June: None.

To cite this abstract in AMA style:

Rubia A, Olsen N, Suman S, Banks S, Albano Aluquin S, Pepper K, June R. Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis: A Clinical Educational Workshop [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/clinical-disease-activity-index-cdai-for-rheumatoid-arthritis-a-clinical-educational-workshop/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-disease-activity-index-cdai-for-rheumatoid-arthritis-a-clinical-educational-workshop/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology